Zacks Research Upgrades Sensus Healthcare (NASDAQ:SRTS) to Hold

Sensus Healthcare (NASDAQ:SRTS) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

SRTS has been the topic of a number of other research reports. HC Wainwright cut their price target on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Lake Street Capital cut their price target on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Sensus Healthcare currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $3.29 on Wednesday. The firm has a 50 day simple moving average of $3.25 and a 200-day simple moving average of $4.18. The firm has a market cap of $54.09 million, a PE ratio of -54.83 and a beta of 1.38. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million. As a group, sell-side analysts expect that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds have recently made changes to their positions in the business. American Century Companies Inc. raised its stake in shares of Sensus Healthcare by 12.7% in the 1st quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock valued at $106,000 after acquiring an additional 2,520 shares during the period. Geode Capital Management LLC raised its stake in shares of Sensus Healthcare by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after acquiring an additional 3,766 shares during the period. Sachetta LLC raised its stake in shares of Sensus Healthcare by 3.0% in the 2nd quarter. Sachetta LLC now owns 128,675 shares of the company’s stock valued at $610,000 after acquiring an additional 3,788 shares during the period. IFP Advisors Inc raised its stake in shares of Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock valued at $89,000 after acquiring an additional 5,100 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Sensus Healthcare by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company’s stock valued at $672,000 after acquiring an additional 5,289 shares during the period. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.